Ipamorelin: the clean growth-hormone peptide behind the stack

You have probably met ipamorelin without meaning to. It is the second name in CJC-1295 and ipamorelin — the pairing half the internet reaches for the moment growth hormone comes up. On its own, it is the quieter and more interesting half: a small peptide built to ask your own body for a clean pulse of growth hormone, and not much else. That restraint is the whole story here, and it is a genuinely appealing one.

What the clean pulse could do for you

Growth hormone sits behind a lot of what you stop taking for granted in your thirties — the deep sleep, the recovery that used to be automatic, the body that held muscle and shed fat without much of a fight. Ipamorelin does not hand you growth hormone. It presses your own release button. Your pituitary — the gland that runs your GH — puts out a pulse of it, the way it does on its own overnight.

For a man who cares about recovery, sleep, and how his body holds its shape, the appeal fits in one line: the signal you want, with less of the mess you don’t. In a category where the side effects are the part everyone quietly worries about, being the tidy one is a real edge. That is the promise. The rest of this page is how far it actually holds.

Why they call it the clean one

The clean label is earned, and it comes from a specific design choice. The earlier peptides in this family worked, but they were sloppy — they pushed growth hormone and dragged the stress hormones up alongside it, cortisol and prolactin and the extras nobody asked for. Ipamorelin was built to skip them.

Novo Nordisk chemists put it together in the 1990s as a five-building-block peptide with one job and no ambitions beyond it. Raun and colleagues, in 1998, gave it the title that stuck: the first selective growth-hormone secretagogue. In their animal work it did exactly what the name says — a strong, clean pulse of GH with the stress-hormone noise left behind. There is even an early hint it does more than release growth hormone. A 2000 rat study by Svensson and colleagues found that weeks of ipamorelin raised bone density without disturbing the tissues it was not aimed at. Still animals. But it fits the pattern: the compound doing its one thing, and only that.

Why it is always sold as half a pair

So why does ipamorelin almost never travel alone? Because CJC-1295 is the obvious other half of the idea. CJC-1295 works the same growth-hormone system on a slower clock, and ipamorelin adds the sharp, clean pulse on top. Two angles on one signal. On paper, they fit together neatly.

On paper is the operative phrase. Nobody has shown the pairing changes anything you would feel in an actual person — the strongest thing anyone can point to is a single mouse study. If you want the pairing taken apart properly, with the trial and the numbers named, the ipamorelin deep-dive walks through it.

How far the proof actually goes

Now the part the stack-sellers skip. Everything above tells you ipamorelin releases growth hormone cleanly and predictably. None of it tells you that a clean pulse turns into anything you would notice — more muscle, deeper sleep, faster recovery. That is a separate question. And it has been put to a proper human test exactly once.

Ipamorelin went into one real clinical trial, years ago, for a hospital use that has nothing to do with performance. It came back null — no meaningful edge over a placebo — and the company running it shut the programme down. No one has taken ipamorelin into a larger human trial since, for any use. The deep-dive names that trial and its numbers; the short version is that the mechanism is proven and the payoff is not.

So here is the honest read. Ipamorelin does one thing well, and it does it cleanly. Whether that clean pulse changes anything you would actually feel, nobody has yet shown in a person. Both of those are true at the same time — and anyone selling you certainty in either direction is selling.

Where the regulators already landed

The regulators have had their look already. In October 2024 the FDA’s compounding advisory committee reviewed ipamorelin and voted against putting it on the list of substances pharmacies are cleared to compound, citing thin human safety and efficacy data. Say that plainly, because not on the current docket would hand you the wrong picture. Ipamorelin is not waiting in the queue for a review — it already had one, and the answer, for now, was no. What that review process actually decides is a longer story, and we walk through it here.

Anti-doping is simpler. Ipamorelin sits inside WADA’s prohibited category, in and out of competition, as a growth-hormone releaser. If you get tested, treat it as banned and check the current code on the day — these lists move.

What a legitimate ipamorelin looks like

Here is the part worth real excitement, and it is nothing like ordering a vial off a research-chemical site and hoping. Picture a physician writing an actual prescription against an actual reason to use it. A US-licensed pharmacy compounding it under real controls. A test on every batch before it reaches you. That is the setting where a genuinely clean mechanism finally earns the honest human trial it has never had.

That is what Wolverine Health is being built to be — the legitimate version of a thing plenty of people already buy the illegitimate way. The regulation has to move first, which is the honest reason the door is not open today. Leave your email. We will tell you the day ipamorelin can be done properly — not sold as half a stack, but tested the way it deserves.